Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 13;13:7851–7858. doi: 10.2147/CMAR.S331076

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Huang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Levels of plasma PKM2 in healthy individuals, AML patients and ALL patients. Plasma samples from AML patients (n= 56), ALL patients (n= 40), AML healthy individuals (n = 29) and ALL healthy individuals (n = 37) were quantified by ELISA. (A) AML patients displayed significantly higher levels of PKM2 (593.11±495.30 pg/mL) compared with healthy individuals (268.12±131.67 pg/mL) (p<0.01). (B) The levels of PKM2 in the plasma in the ALL patients (495.05±327.27 pg/mL) had a significant increase compared with healthy individuals (230.13±147.63 pg/mL) (p<0.05). *p < 0.05; **p < 0.01.